Request more information about Prostate Pathology products.
Please complete the form below to speak with a Roche representative.
Prostate cancer is a major public health concern. Approximately 1 man in 7 will be diagnosed with prostate cancer in his lifetime.1 This makes prostate cancer the second most common cancer and the sixth most common cause of death from cancer in men worldwide.2 Approximately 70% of prostate cancer cases are low risk, yet up to 90% are treated aggressively.3
Recent translational research is showing that much like soft tissue cancers, prostate cancer can now be molecularly subtyped with immunohistochemistry techniques, which may enable the identification of aggressive versus indolent disease. We are committed to the development of innovative tools to better identify and subtype prostate cancer — so you can deliver the right test, with confidence, in the shortest possible time.
1. American Cancer Society. What are the key statistics about prostate cancer? American Cancer Society Website. http://www.cancer.org/cancer/prostatecancer/detailedguide/prostate-cancer-key-statistics. Revised 14 Dec 2012. Accessed 9 Nov 2012.
2. Cancer Research UK. Prostate Cancer. http://www.cancerresearchuk.org/cancer-info/cancerstats/world/prostate-cancer-world/
3. Hayes et al. Active Surveillance Compared With Initial Treatment for Men With Low-Risk Prostate Cancer A Decision Analysis. JAMA. 2010; 304(21): 2373-2380. doi:10.1001/jama.2010.1720.
4. Zhou M et al. Basal cell cocktail (34betae12 + p63) improves the detection of prostate basal cells. AM J Surg Pathol. 2003; 27: 365-71.
5. Shah R B, et al. The diagnostic use of ERG in resolving an “atypical glands suspicious for cancer” diagnosis in prostate biopsies beyond that provided by basal cell and α-methylacyl-CoAracemase markers. Human pathology. 2013; 44(5): 786 -794.
6. Weischenfeldt et al. Integrative Genomic Analyses Reveal an Androgen-Driven Somatic Alteration Landscape in Early-Onset Prostate Cancer. Cancer Cell. 2013; 23:159-170.
7. Park, K et al. Antibody-based detection of ERG rearrangement-positive prostate cancer. Neoplasia. 2010; 12(7): 590.
Outside of Pepper mode, this text will be replaced by the resource cards.
Outside of Pepper mode, this text will be replaced by the content added in the above "Contact a Rep HTML" code editor.
Prostate PathologyAndrogen Receptor (SP107) Rabbit Monoclonal Primary Antibody
Basal Cell Cocktail (34ßE12+p63), 50, VENTANA
Basal Cell Cocktail (34ßE12+p63), 250, VENTANA
ERG (EPR3864) Rabbit Monoclonal Primary Antibody
EZH2 (SP129) Rabbit Monoclonal Primary Antibody
NKX3.1 (EP356) Rabbit Monoclonal Primary Antibody
p63 (4A4) Mouse Monoclonal Primary Antibody, VENTANA
p504s (SP116) Rabbit Monoclonal Primary Antibody
Prostate Specific Antigen (PSA) Rabbit Polyclonal Primary Antibody, CONFIRM
PTEN (SP218) Rabbit Monoclonal Primary Antibody